focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Hey abzzba,
I wanted to plough through the web to find source data, but you've made reference to them, thanks, appreciate it!
BR
LR
Ranger,
Assuming the figures quoted by ARahim are correct (they're posted by another member of this board via twitter link), all I am saying that current (assumed) full production annual revenue is very close to current market cap of Echo.
No doubt that the actual figures are much less; the company isn't too transparent with actual sales figures in its operational updates, but the annual results can't be too far away, so I guess we will find out the state of affairs as at 31/12/20 quite soon.
So at the moment the market priced us at revenue from assumed full year's capacity (£14m = circa $20.6m)
Hi all,
Congrats to everyone who made monieeeee here, well done!
Genuine question - where can I find how many shares in issue were there in previous years?
Thanks in advance
LR69
This is old news:
https://www.bmj.com/content/371/bmj.m4509/rr-1
Furthermore, this isn't a Cuban drug, it's Russian, and has been around for ages (use google translate):
https://www.firnm.ru/2020/01/3543-efficacy-grippferon-prevention-and-treatment-coronavirus-infection/
Extract:
"In the midst of the SARS-Cov epidemic, "atypical pneumonia", in 2003, a study was carried out at the Research Institute of Influenza of the Russian Academy of Medical Sciences to assess the virus-inhibiting effect of Grippferon® on a model of coronavirus infection in cell culture. As a result, data were obtained indicating that the drug has direct inhibitory activity against human coronavirus. When using the drug, the virus multiplication rate is significantly reduced, which makes it possible to consider the drug Grippferon® as one of the most promising means of preventing and treating coronavirus infection".
Nasal interferons are widely used in the post-soviet states as therapeutics for colds and flus, here are links to some of these:
https://rupharma.com/grippferon-interferon-alfa-2b/
https://rupharma.com/ingaron-interferon-gamma/
These have been around for years. If they were really so effective at preventing Covid19, I'm pretty sure the press would have been all over it. Well, either that, or it's a huge conspiracy and we can't see what's right in front of us, and the crab-people have won the game.
The guy had a bunch of shares for a long time. He also recently got awarded a bunch of options exercisable at 1.4p. These are call options, not put options. These options can be exercised anytime between now and 5 years down the line (if I recall correctly). The way I read it - he sold the shares and locked in the profit at just over 3x his option strike price. Considering he has been (allegedly) investing a bunch of his own cash to bank roll this company, he got his money back, plus some profit, whilst keeping his options open, so to speak, to partake in the gains if this comes to fruition of being sold/licensed globally. If it doesn't, then he got his money back with some profit. Cutting the risks in other words. RMS needs to loose half it's price and stay there for the next 5 years for these options to eventually be worthless.
...but boy did someone get shafted on the open. The screen showed minus 22% during first couple of minutes of trading. Now back into blue zone.
Mid price is 2.9p at the moment, bang on at the 38% retracement level between start of the rally (1.3p, open on Wed 11 of Nov) and the beginning of the retrace (yesterday ope, 5.69p), if you look at daily candles.
Hi CityTT
Are you looking at a daily or hourly chart?
What's the target if one's looking at a chart in isolation?
Thanks Thoth,
Would certainly be spiffing if so...
Top of the evening everyone!
It's a combination of it being a long day and me not being the sharpest tool in the box, but how is the Gilead news relatable to SAR?
I am correct understanding that it's assumed that now that this trial has failed, Gilead will be approaching SAR? If so, is this a speculation/educated speculation/knowledge?
Sorry if it's a daft question,
Best regards,
LR
Thanks Thoth, I'll have a closer look at the previous RNS's on these,
Regards,
LR
Good point re mCap.
I did take a small punt here, and clearly it is going in right direction.
I'm still doing my research on here, but it evident (and please correct me if I'm wrong) that the only piece of imminent tangible news that can be expected short terms (days/weeks) is the Gov grant.
Comparing this to likes of SNG (my largest holding) or ODX/GDR etc isn't perhaps yet justified - the pharma companies that delivered spectacular growth in SP and mCap did so because of the reasonable expectation of either imminent cashflow and/or possible takeovers - there isn't grounds to be expecting either for SAR today.
Having said that, SAR has mCap of about £50mil (well, actually 60 as at this afternoon, if not more), and with stocks it's always about market perception of potential. Clearly potential is good here, question is, even based on comparables, how much is this worth today, and whether the RNS (whenever it lands) would lift the mood further.
@ScoobyDooLondon
Based on the Northern Rock example back in 2007 (my first stock market investment), I am guessing not much to say the least.
Hey Rickee,
Would be interesting to see your TA on this. Post a link to a screenshot perhaps or to a twitter page with the TA please?
I guess Gov and WHO can't really push anything until the anything is official, so it's all about peer review and gov. approval.
No offer was made, it would have to be reported if there was. I can't wait for these to start coming in though,
Agreed about SNG being event-driven, however as it becomes a market with active dynamics so to speak, more people inevitably turn to charts. Good point on having them in one's tool box.
Congratulations to all investors here, and really hope a lot of people will suffer much much less as the result of this breakthrough.
Hope enough people are tagging Trump with the news lol
GLA!
Has been for a while now by the looks of it.